Results 121 to 130 of about 37,267 (288)
Skeletal muscle and subcutaneous fat quantity as prognostic indicators in cardiac amyloidosis
European Journal of Heart Failure, EarlyView.Aims Disease‐related changes in body composition are associated with worse outcomes in chronic heart failure. In cardiac amyloidosis (CA), the prognostic value of direct body composition measures is understudied. Methods and results We identified 160 consecutive patients with CA (transthyretin [ATTR] or light chain [AL]) diagnosed between 2001 and 2021
Joshua Longinow +4 more
wiley +1 more source
Systemic Amyloidosis with Cardiac Involvement: Features of Course and Diagnostic Difficulties
Архивъ внутренней медициныThe diversity of clinical forms of amyloidosis is related to differences in amyloidogenic precursor proteins. Cardiac involvement is characteristic of AL- and ATTR-amyloidosis, with cardiac involvement developing in the vast majority of patients with AL ...
E. V. Voloshinova +3 more
doaj +1 more source
Living Donor Kidney and Autologous Stem Cell Transplantation for Primary Systemic Amyloidosis (AL) with Predominant Renal Involvement [PDF]
, 2005 Nelson Leung +12 more
openalex +1 more source
European Journal of Heart Failure, EarlyView.Heart failure (HF) with supranormal ejection fraction (HFsnEF) is an unnoticed but emerging entity in HF. This study showed that HFsnEF carries a similarly increased cardiovascular risk as HF with reduced ejection fraction (HFrEF) and distinct structural and proteomic characteristics from HFrEF, warranting a further comprehensive understanding and ...
Yasuhiko Sakata +19 more
wiley +1 more source
PRIMARY AMYLOIDOSIS (AL) AS A CAUSE OF NEPHROTIC SYNDROME [PDF]
, 2005 Yoann Bataille +6 more
openalex +1 more source
Refining therapy for AL amyloidosis
Blood, 2006 Comment on Seldin et al, page [3945][1] In this issue, Seldin and colleagues report that the benefits of high-dose melphalan chemotherapy and autologous peripheral blood stem cell transplantation (SCT) can be safely extended to selected patients 65 years or older with immunoglobulin light-chain (
openaire +3 more sources
European Journal of Heart Failure, EarlyView.Long‐term efficacy of tafamidis in patients with ATTR‐CM in ATTR‐ACT and its LTE by NAC stage at ATTR‐ACT baseline. ATTR‐ACT, Tafamidis in Transthyretin Cardiomyopathy Clinical Trial; ATTR‐CM, transthyretin amyloid cardiomyopathy; NAC, National Amyloidosis Centre.
Thibaud Damy +4 more
wiley +1 more source
Response to Goodman et al.: Amyloidosis, not myeloma [PDF]
, 2005 J. A. Child +2 more
openalex +1 more source